Literature DB >> 25844164

Salvage Regimens Containing Darunavir, Etravirine, Raltegravir, or Enfuvirtide in Highly Treatment-Experienced Perinatally Infected Pregnant Women.

Gail F Shust1, Jennifer Jao2, Gabriela Rodriguez-Caprio2, Roberto Posada1, Katherine T Chen3, Amelia Averitt4, Rhoda S Sperling3.   

Abstract

Combination antiretroviral therapy in pregnant women with human immunodeficiency virus has dramatically decreased maternal-to-child transmission. Highly treatment-experienced pregnant patients have limited effective treatment options due to past toxicities and viral resistance. We present 8 pregnancies in 7 perinatally infected women successfully treated with salvage regimens containing darunavir, etravirine, raltegravir, or enfuvirtide.
© The Author 2013. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  darunavir; enfuvirtide; etravirine; pregnancy; raltegravir

Year:  2013        PMID： 25844164      PMCID： PMC4381746          DOI： 10.1093/jpids/pit019

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  10 in total

1.  High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.

Authors:  Denise A McKeown; Melanie Rosenvinge; Sheila Donaghy; Mike Sharland; David W Holt; Ian Cormack; Phillip Hay; S Tariq Sadiq
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

2.  Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.

Authors:  Jelena Ivanovic; Rita Bellagamba; Emanuele Nicastri; Fabrizio Signore; Cristina Vallone; Massimo Tempestilli; Chiara Tommasi; Luisa Mazzitelli; Pasquale Narciso
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

3.  Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance.

Authors:  André Furco; Bhairvi Gosrani; Sara Nicholas; Amanda Williams; Wunmi Braithwaite; Anton Pozniak; Graham Taylor; David Asboe; Hermione Lyall; Andrew Shaw; Moses Kapembwa
Journal:  AIDS       Date:  2009-01-28       Impact factor: 4.177

4.  U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

Authors:  Lynne M Mofenson
Journal:  MMWR Recomm Rep       Date:  2002-11-22

5.  Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women.

Authors:  P Izurieta; T N Kakuda; C Feys; J Witek
Journal:  HIV Med       Date:  2011-04       Impact factor: 3.180

6.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  R S Sperling; D E Shapiro; R W Coombs; J A Todd; S A Herman; G D McSherry; M J O'Sullivan; R B Van Dyke; E Jimenez; C Rouzioux; P M Flynn; J L Sullivan
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

7.  A United States national reference for fetal growth.

Authors:  G R Alexander; J H Himes; R B Kaufman; J Mor; M Kogan
Journal:  Obstet Gynecol       Date:  1996-02       Impact factor: 7.661

8.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

9.  Raltegravir in pregnancy: a case series presentation.

Authors:  N Taylor; V Touzeau; M Geit; M Gisinger; A Egle; R Greil; A Rieger; R Zangerle
Journal:  Int J STD AIDS       Date:  2011-06       Impact factor: 1.359

10.  Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025.

Authors:  Jennifer S Read; Yanling Huo; Kunjal Patel; Marcia Mitchell; Gwendolyn B Scott
Journal:  J Pediatric Infect Dis Soc       Date:  2012-05-03       Impact factor: 3.164
  10 in total
  3 in total

1.  Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.

Authors:  Lisa Rahangdale; Jordan Cates; JoNell Potter; Martina L Badell; Dominika Seidman; Emilly S Miller; Jenell S Coleman; Gweneth B Lazenby; Judy Levison; William R Short; Sigal Yawetz; Andrea Ciaranello; Elizabeth Livingston; Lunthita Duthely; Bassam H Rimawi; Jean R Anderson; Elizabeth M Stringer
Journal:  Am J Obstet Gynecol       Date:  2016-03       Impact factor: 8.661

2.  A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses.

Authors:  Yufeng Yu; Yong-Qiang Deng; Peng Zou; Qian Wang; Yanyan Dai; Fei Yu; Lanying Du; Na-Na Zhang; Min Tian; Jia-Nan Hao; Yu Meng; Yuan Li; Xiaohui Zhou; Jasper Fuk-Woo Chan; Kwok-Yung Yuen; Cheng-Feng Qin; Shibo Jiang; Lu Lu
Journal:  Nat Commun       Date:  2017-07-25       Impact factor: 14.919

3.  Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.

Authors:  Nikki Mulligan; Stein Schalkwijk; Brookie M Best; Angela Colbers; Jiajia Wang; Edmund V Capparelli; José Moltó; Alice M Stek; Graham Taylor; Elizabeth Smith; Carmen Hidalgo Tenorio; Nahida Chakhtoura; Marjo van Kasteren; Courtney V Fletcher; Mark Mirochnick; David Burger
Journal:  Front Pharmacol       Date:  2016-08-04       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.